ASX:IMU
Imugene Ltd
Location: Australia
Response Rate
1 of 1 questions answered
Rate Your
Company Satisfaction
Help us improve
Congratulations on successfully completing the first safety observation period for the IV combination arm of the OASIS trial, which signals a promising start. With this positive early indication, when can shareholders expect initial safety and early efficacy data readouts, and how will these results guide Imugene’s decision-making around dose escalation, combination strategies, or potential partnerships?
Thank you for your email.
We note your comments and these will be addressed at the webinar on Wednesday 16 April at 11:00am AEST
Imaging's clinical data and expert team drive cancer treatment innovation
About 80,000 patients diagnosed with DLBCL annually in the US
FDA Fast Tracks Life-Saving Cancer Therapy with 57% Success Rate